Bevacizumab Market Report 2025 (Global Edition)

Global Bevacizumab Market Report 2025 Market Size Split by Type Outlook: (Injection, Solution, Other), by Application Outlook: (Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer (CRC), Ce...

Bevacizumab Market Report Description

We have various report editions of Bevacizumab Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Bevacizumab Market Insights Video

Competitive Landscape of the Bevacizumab Market

Leading companies in the bevacizumab market are utilizing a number of techniques to increase revenue and establish strong brands. These include coming up with innovative ways to differentiate their product, collaborating and developing strategic alliances, keeping prices and costs competitive, and emphasizing safety and post-market surveillance. Moreover, boosting marketing initiatives, entering international markets, and putting patient access initiatives into place is essential for building a strong brand and gaining market dominance. Pharmaceutical companies are collaborating strategically to improve their skills in research, development, and distribution. This will help them deliver bevacizumab therapies more effectively and widely.

Top Companies Market Share in Bevacizumab Industry: (In no particular order of Rank)

• Genentech (U.S.)
• Amgen (U.S.)
• Pfizer Inc. (U.S.)
• Allergan (Ireland)
• Biocon (India)
• Reliance Life Sciences (India)
• Beacon Pharmaceuticals Limited (Bangladesh)
• Celgene Corporation (U.S.)
• Mylan Inc. (U.S.)
• Dr. Reddy’s Laboratories Ltd (India)
• Eli Lilly and Company (India)
• BioXpress Therapeutics (Switzerland)
• Teva Pharmaceutical industries Ltd. (Isarel)
• CELLTRION INC. (South Korea)
• FUJIFILM KYOWA KIRIN BIOLOGICS Co.
• Ltd. (Japan)
• Hetero Drugs (U.S.)
• AryoGen Pharmed (Iran)
• Zydus Cadila (India)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Bevacizumab Market

Which Region Dominates the Bevacizumab Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. The growing incidence of cancer, the growing use of targeted therapies, and improvements in medication formulation are driving the expansion of the bevacizumab market in North America. A move toward customized medicine and combination medicines that increase therapeutic efficacy are two important themes. There are prospects to broaden the list of conditions for which bevacizumab is indicated, including more cancer types and its usage in ocular disorders. Furthermore, price and accessibility are anticipated to be impacted by continuing research and development, as well as the possible introduction of biosimilars. Higher healthcare spending and better diagnostic tools that enable earlier and more accurate cancer detection are driving the market's expansion.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Bevacizumab market. The expanding frequency of cancer, rising healthcare spending, and expanding knowledge of cutting-edge cancer treatments are the main factors driving the Asia Pacific bevacizumab market. Greater access to top-notch medical care is a result of the region's economic expansion. Better treatment outcomes and early cancer identification are a result of growing healthcare infrastructure and advances in diagnostics. The growing use of targeted medicines and a sizable patient population also create huge market potential. Additionally, anticipated improvements in treatment options and the advancement of market expansion in the region will be made by the introduction of biosimilars and ongoing clinical research.

The current report Scope analyzes Bevacizumab Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Bevacizumab Market Analysis

According to Cognitive Market Research, the global Bevacizumab market size was estimated at USD 7158.6 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 2863.44 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Bevacizumab market with a market size of USD 2259.25 million in 2024 and is projected to grow at a CAGR of 7.7% during the forecast period. The substantial incidence of cancer in the United States has led to a strong demand for the angiogenesis inhibitor bevacizumab. Its use has been fueled by its efficacy in treating a variety of malignancies, including lung, renal cell, and colorectal cancer.
• The Canada Bevacizumab market had a market share of USD 343.61 million in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period. Bevacizumab demand in Canada is heavily impacted by government healthcare programs that attempt to improve access to cancer treatment.
• The Mexico Bevacizumab market is projected to witness growth at a CAGR of 8.4% during the forecast period, with a market size of USD 260.57 million in 2024.

Europe Bevacizumab Market Analysis

According to Cognitive Market Research, the global Bevacizumab market size was estimated at USD 7158.6 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 2147.58 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.

• The United Kingdom Bevacizumab market had a market share of USD 360.79 million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. Because of the rising incidence of cancer and the growing usage of targeted therapies, the bevacizumab market in the United Kingdom is booming. Three major developments in customized medicine are the growing use of biosimilars, the rise in R&D for novel indications, and more.
• The France Bevacizumab market is projected to witness growth at a CAGR of 7.4% during the forecast period, with a market size of USD 197.58 million in 2024.
• According to Cognitive Market Research, the German Bevacizumab market size was valued at USD 425.22 million in 2024 and is projected to grow at a CAGR of 8.4% during the forecast period. In Europe, Bevacizumab is being used more frequently in German clinics to enhance patient outcomes because they have a strong emphasis on customized cancer care and a state-of-the-art medical infrastructure. The increased need for this medication is a result of both the rising incidence of cancer and the improvements in available treatments.
• The Italy Bevacizumab market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 184.69 million in 2024.
• The Russia Bevacizumab market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 332.87 million in 2024.
• The Spain Bevacizumab market is projected to witness growth at a CAGR of 7.3% during the forecast period with a market size of USD 176.10 million in 2024
• The Luxembourg Bevacizumab market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD 66.57 million in 2024.
• The Portugal Bevacizumab market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 45.10 million in 2024.
• The Greece Bevacizumab market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 25.77 million in 2024.
• Rest of Europe's Bevacizumab market is projected to witness growth at a CAGR of 6.9% during the forecast period, with a market size of USD 332.87 million in 2024.

Asia Pacific Bevacizumab Market Analysis

According to Cognitive Market Research, the global Bevacizumab market size was estimated at USD 7158.6 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 1646.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2031.

• According to Cognitive Market Research, the China Bevacizumab market size was valued at USD 740.92 million in 2024 and is projected to grow at a CAGR of 11.2% during the forecast period. The demand for cutting-edge and efficient cancer treatments like bevacizumab has increased as China's healthcare system develops with more sophisticated infrastructure and easier access.
• The Japan Bevacizumab market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 227.21 million in 2024.
• The India Bevacizumab market had a market share of USD 197.58 million in 2024 and is projected to grow at a CAGR of 13.5% during the forecast period. The increased incidence of cancer and the progress made in biotechnology have led to an increase in the demand for bevacizumab, a monoclonal antibody used to treat different types of cancer, in India.
• The South Korean Bevacizumab market is projected to witness growth at a CAGR of 10.8% during the forecast period, with a market size of USD 164.65 million in 2024.
• The Australian Bevacizumab market is projected to witness growth at a CAGR of 11.4% during the forecast period, with a market size of USD 85.62 million in 2024.
• The South East Asia Bevacizumab market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 113.61 million in 2024.
• The Rest of the Asia Pacific Bevacizumab market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 116.90 million in 2024.

South America Bevacizumab Market Analysis

According to Cognitive Market Research, the global Bevacizumab market size was estimated at USD 7158.6 Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD 357.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Bevacizumab market size was valued at USD 153.19 million in 2024 and is projected to grow at a CAGR of 9.7% during the forecast period. Bevacizumab is a vital medication used to treat a variety of malignancies, including ovarian, lung, and colorectal cancers. There is a considerable demand for cancer awareness regarding this medication in Brazil. The public has to be made more aware of the advantages and drawbacks of bevacizumab as cancer rates rise. Awareness campaigns are essential to make sure that patients and healthcare professionals are aware of the drug's function, possible adverse effects, and the significance of using it in a timely and suitable manner.
• Argentina's Bevacizumab market had a market share of USD 60.13 million in 2024 and is projected to grow at a CAGR of 10.0% during the forecast period. The need for government funding for bevacizumab, a vital drug used to treat a variety of malignancies and eye disorders, is rising in Argentina.
• Colombia Bevacizumab market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD 31.86 million in 2024.
• Peru Bevacizumab market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 29.35 million in 2024.
• Chile Bevacizumab market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 25.77 million in 2024.
• The Rest of Latin America's Bevacizumab market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 57.63 million in 2024.

Middle East Bevacizumab Market Analysis

According to Cognitive Market Research, the global Bevacizumab market size was estimated at USD 7158.6 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 143.17 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031..

• The GCC Countries Bevacizumab market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 61.28 million in 2024. The Gulf Cooperation Council (GCC) countries have experienced a notable increase in demand for bevacizumab, a monoclonal antibody used in cancer treatment, as a result of increased cancer rates. Changes in lifestyle, environmental variables, and enhanced diagnostic capabilities are all credited for this increase.
• The Egypt Bevacizumab market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 15.03 million in 2024.
• The South Africa Bevacizumab market is projected to witness growth at a CAGR of 10.4% during the forecast period, with a market size of USD 22.62 million in 2024. The necessity for effective treatments and the rising incidence of cancer in South Africa are driving demand for healthcare initiatives employing bevacizumab.
• The Turkey Bevacizumab market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD 12.31 million in 2024.
• The Nigeria Bevacizumab market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 15.03 million in 2024.
• The Rest of the MEA Bevacizumab market is projected to witness growth at a CAGR of 8.4% during the forecast period, with a market size of USD 16.89 million in 2024.

Bevacizumab Market Analysis

How are Segments Performing in the Global Bevacizumab Market?

Bevacizumab Market Type Segment Analysis

According to Cognitive Market Research, Injection stands out as the dominant category over the projected period. Due to bevacizumab's success in treating a variety of malignancies, including lung, kidney, and colorectal tumors, there is an increasing need for these injections. Bevacizumab is an essential therapeutic option for patients with advanced-stage malignancies since it is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to limit tumor growth. Rising demand in the worldwide market is a result of rising patient numbers, improved anticancer therapies, and greater knowledge of its advantages. Furthermore, its usage in both established and novel cancer therapies is probably going to be further pushed by continued research and development.

Solution emerges as the fastest-growing category in the Bevacizumab market. Bevacizumab's critical function in treating a variety of malignancies and other disorders is driving demand for solutions in the market. A monoclonal antibody called bevacizumab suppresses vascular endothelial growth factor (VEGF), which aids in controlling the development and spread of tumors. Bevacizumab solutions are among the effective therapies that are in high demand due to the rising incidence of cancers, including lung, kidney, and colorectal cancers. The growing demand for bevacizumab-based therapies is also attributed to the development of personalized medicine and biotechnology. Ongoing research and clinical trials, which broaden its medicinal indications and applications, also have an impact on the market. The market for bevacizumab products is expanding as medical professionals look for more specialized and potent therapies.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Bevacizumab Industry. Request a Free Sample PDF!

Bevacizumab Market Application Segment Analysis

According to Cognitive Market Research, the dominant category is Cancer. Because bevacizumab effectively inhibits the growth of tumors by targeting vascular endothelial growth factor (VEGF), it is still in high demand in the market for cancer treatments. Bevacizumab is a monoclonal antibody that works by stopping the growth of tumor blood vessels to treat a variety of cancers, such as kidney, lung, and colorectal tumors. Due to its substantial therapeutic benefits, oncologists and patients have considerable demand for this technique. The bevacizumab market expansion is fueled by the rising incidence of cancer worldwide as well as the approval of multiple indications for it. Ongoing research and developments in combination treatments further drive the need for bevacizumab in oncology.

The fastest-growing category in the Bevacizumab market is Eye Diseases. Bevacizumab's effectiveness in treating illnesses such wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) has led to a boom in demand for the drug in the market for eye ailments. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF). It aids patients by lowering aberrant blood vessel growth and fluid leakage. The market is driven by the rising incidence of various eye conditions as well as the aging population. Additionally, the growing usage of bevacizumab in ophthalmology is attributed to improvements in diagnostic tools and increased public awareness of eye health.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Bevacizumab Product Segment Analysis

• Avastin
• Mvasi
• Zirabev
• Versavo
• Others

Bevacizumab Distribution Channel Segment Analysis

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion